Cargando…
Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis
BACKGROUND: Trastuzumab deruxtecan (T-DXd) has been shown to benefit progression-free survival and overall survival in patients with metastatic breast cancer (mBC) after progression on ≥1 human epidermal growth factor receptor 2 (HER2)-targeted therapies. However, interstitial lung disease (ILD) and...
Autores principales: | Soares, L.R., Vilbert, M., Rosa, V.D.L., Oliveira, J.L., Deus, M.M., Freitas-Junior, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485391/ https://www.ncbi.nlm.nih.gov/pubmed/37481956 http://dx.doi.org/10.1016/j.esmoop.2023.101613 |
Ejemplares similares
-
Trastuzumab deruxtecan for breast cancer
Publicado: (2022) -
Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report
por: de Weger, Vincent A., et al.
Publicado: (2023) -
Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report
por: Riudavets, Mariona, et al.
Publicado: (2022) -
Two cases of trastuzumab deruxtecan‐induced interstitial lung disease in advanced breast cancer
por: Gocho, Kyoko, et al.
Publicado: (2022) -
Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan
por: Baba, Tomohisa, et al.
Publicado: (2023)